PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	175-208	phosphopantothenoylcysteine synthetase	Homo sapiens	50-84	
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	175-208	phosphopantothenoylcysteine synthetase	Homo sapiens	86-90	
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	210-218	phosphopantothenoylcysteine synthetase	Homo sapiens	50-84	
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	210-218	phosphopantothenoylcysteine synthetase	Homo sapiens	86-90	
32033912-8	2020	In an intravenous (IV) HPbetaCD trial, plasma PPCS in all patients was significantly reduced.	2-hydroxypropyl-beta-cyclodextrin	23-31	phosphopantothenoylcysteine synthetase	Homo sapiens	46-50	
32033912-9	2020	These results demonstrate that plasma PPCS was able to diagnose NPC1 patients with high sensitivity and specificity, and to evaluate the peripheral treatment efficacy of IV HPbetaCD treatment.	2-hydroxypropyl-beta-cyclodextrin	173-181	phosphopantothenoylcysteine synthetase	Homo sapiens	38-42